Biosynex Wins $5.7M BARDA-Supported Award for Biothreat Test
Subsidiary Chembio received a BARDA-supported award to advance its DPP Biothreat Panel over 20 months, aiming for FDA clearance of a rapid multiplex test for three pathogens and integration with the DPP Micro Reader.
BIOSYNEX SA said its subsidiary Chembio received a $5.7M BARDA-supported award to advance the DPP Biothreat Panel over 20 months. The work aims to secure FDA clearance for a rapid multiplex test covering three pathogens and to integrate it with the DPP Micro Reader.